Merck (MRK) announced new long-term data highlighting the sustained survival benefits of Keytruda, Merck’s anti-PD-1 therapy, in treating non-small cell lung cancer. The results are based on the ...

Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna and MSD's mRNA cancer vaccine A combination of Moderna and MSD's personalised cancer vaccine, intismeran autogene, and MSD ...

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a KEYTRUDA-based regimen in an earlier stage of cancer to ...

Patients with early triple-negative breast cancer had improved survival outcomes after receiving presurgical Keytruda plus chemotherapy and postsurgical Keytruda. Patients with early-stage ...

Keytruda, known scientifically as pembrolizumab, is an immunotherapy drug that has transformed cancer treatment for many patients worldwide. Traditional chemotherapy works by directly attacking the ...

The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. After questioning the benefits of checkpoint inhibitors in stomach cancer cases without ...